# PT-141

FDA-approved melanocortin libido drug; works strongly for many, raises blood pressure.

- Page: https://peprank.xyz/peptides/pt-141
- Category: Hormones & libido (Research peptide)
- Also known as: bremelanotide; Vyleesi
- Routes: Nasal / Injection
- Sequence: DHFRWK (bremelanotide: Ac-Nle- N-terminus, D-Phe, cyclic (Asp-Lys lactam), free C-terminal acid)
- Safety tier: Strict: Avoid · Balanced: Avoid · Evidence only: Avoid
- Risk axes (0 none to 3 severe): Seen harm 2, Mechanism 2, Data gap 0, Silent harm 2, Product 3
- Positive: 38% of 31 graded reports glowing or positive, shrunk toward the 49% all-report average by 8 reports' weight
- Rank: #57 of 61 research peptides
- Graded reports: 31 (Glowing 7, Positive 4, Mixed 6, Nothing 5, Negative 6, Bad reaction 3)
- Evidence: Approved drug — in the US (2019, premenopausal HSDD, 1.75 mg)
- Access: Approved drug
- Onset: Flushing and nausea within minutes to an hour. The sexual effect is labelled at 45 minutes, but most users report 1-6 hours and a sizeable minority 8-12 hours or only after sleeping.
- Lasts: Effects last roughly 6-24 hours, some users say 2-3 days; nausea lasts 15 minutes to several hours, and a few feel hungover the next day.
- Cost per month: ≈ €24–170 (at 0.25–1.8 mg/day, Semax Polska at €3.16/mg)
- Updated: 2026-10-30

**Why Avoid under the strict bar:** Cardiovascular effects (BP spikes; contraindicated in CVD) and melanocortin pigmentation effects.

## What users report

Polarised. Some users (including post-prostatectomy men) report 'like a teenager' effects and intense orgasms. Others get help only 2-3 times out of 10, and one woman found it purely physical with no desire. Nausea is the main complaint, sometimes severe, plus facial flushing. About 30-40% report weak or no effect.

**Effects:** increased desire/arousal; stronger erections independent of PDE5; more intense orgasm

**Downsides:** nausea (~40% in trials); facial flushing, headache; 'physical-only' arousal; delayed onset (hours)

**Risks:** Transient blood-pressure rise and heart-rate drop after each dose; contraindicated in uncontrolled hypertension / cardiovascular disease; Focal hyperpigmentation with repeated use; Priapism risk (melanocortin class)

**Typical use:** Community starts 250-500 mcg subQ, up to the 1.75 mg label dose, max once per 24 h.

**Getting it:** Vyleesi (1.75 mg autoinjector) is a US prescription drug for premenopausal women with HSDD, capped at 8 doses a month. Men and most Reddit users buy grey-market 10 mg vials or nasal sprays (users find the sprays weak); some US clinics compound it.

**Stacked with:** Tadalafil or sildenafil (The most common pairing, PDE5 for the erection and PT-141 for desire; the ER priapism reports come from this combination.); Ondansetron or an antihistamine (Taken 1-2 hours before the dose; users say it makes the nausea and flushing manageable.); Oxytocin (Suggested and tried by women who found PT-141 purely physical with no emotional desire.); Melanotan II (Same receptor family; long-term MT2 users say MT2 gives a similar libido effect and also tans, while PT-141 users report skin darkening too.)

## Risk profile

- **Seen harm 2/3:** The Vyleesi label warns of a transient blood-pressure rise and focal hyperpigmentation (1% at up to 8 doses a month, but 38% after 8 daily doses, not always reversible); serious adverse reactions were 1.1% vs 0.5% on placebo, including one case of acute hepatitis.
- **Mechanism 2/3:** A melanocortin agonist that raises systolic pressure by up to 6 mmHg for hours after each dose and stimulates melanocytes; contraindicated in uncontrolled hypertension and cardiovascular disease.
- **Data gap 0/3:** FDA-approved since 2019 on two 24-week trials in 1,247 premenopausal women plus a 684-woman 52-week extension. The caveat is fit, not size: post-marketing use is small, and men and the daily dosing common with grey-market vials are outside the trials.
- **Silent harm 2/3:** The blood-pressure rise is silent without a cuff, and pigment changes build up over weeks of frequent dosing; nausea is immediate.
- **Product 3/3:** Most users buy grey-market vials or nasal sprays, which are far cheaper than Vyleesi; PT-141 was among the compounds in the 6,441-sample quality study.
- **Never if:** Uncontrolled hypertension or known cardiovascular disease (label); Dark skin or a history of pigment disorders, with frequent dosing; Pregnancy or breastfeeding (no human reproductive data)

## Top reports

- Glowing, libido, 1.75 mg (Vyleesi autoinjector): “I've used 4 doses now and I'm in love. I've learned it takes closer to 60-90 minutes for it to kick in compared to the 45 minutes the packaging says” — [r/VyleesiUsersCommunity](https://www.reddit.com/r/VyleesiUsersCommunity/comments/1c89960/my_positive_first_experience_with_vyleesi/)
- Glowing, libido, 500 mcg (a quarter of the label dose): “Well that has been my dick in the past 24 hours. I will certainly not be taking even the quarter strength that I did if I decide to take it again.” — [r/erectiledysfunction](https://www.reddit.com/r/erectiledysfunction/comments/1qik4vm/pt141_experience_it_absolutely_works/)
- Glowing, libido, 1.25 mg: “Yes. Fuck yes. 1.25mg has me knocking over lamps” — [r/Biohacking](https://www.reddit.com/r/Biohacking/comments/1vrse1m/does_pt141_work/p4g0tiv/)
- Glowing, libido: “It has been a life changer for me, the normal ED meds were not working well so in desperation I tried it. It works every time but you have to get use to scheduling sex.” — [r/Biohackers](https://www.reddit.com/r/Biohackers/comments/1iypi6c/pt141_gamechanger_or_overrated_need_real/nwh2a2e/)
- Glowing, libido: “I had my prostate removed in 24 and have suffered from ed every since. I was taking max dose of viagra and cialis with no help. Then PT141 entered my life and now im like a teenager!” — [r/erectiledysfunction](https://www.reddit.com/r/erectiledysfunction/comments/1qik4vm/pt141_experience_it_absolutely_works/o11o9me/)

## Cheapest in Europe

- [Semax Polska](https://semaxpolska.com/en/pt-141-40-mg/) (PL): PT-141 40 mg nasal kit, €45, €1.13/mg (also contains 5 mg GHK-Cu, judged as [GHK-Cu (injectable)](https://peprank.xyz/peptides/ghk-cu-injectable) since the nasal route is systemic: Strict Avoid · Balanced Avoid · Evidence only Caution)
- [XL Peptides](https://xlpeptides.com/product/pt-141-10mg/) (GB): PT-141 10mg Research Peptide, €20, €2.03/mg
- [Semax Polska](https://semaxpolska.com/en/pt-141-10-mg-bacteriostatic-water-3ml/) (PL): PT-141 10 mg + bacteriostatic water 3 ml, €32, €3.16/mg
- [Europa-Peptide](https://europa-peptide.de/en/shop/pt-141-10mg/) (PL): PT-141 10mg, €35, €3.49/mg
- [Baltic Peptides](https://balticpeptides.com/product/pt-141/) (LT): PT-141 (Bremelanotide) 10mg vial, €40, €4.00/mg

## Studies

- [Kingsberg et al. 2019: bremelanotide for hypoactive sexual desire disorder, two randomised phase 3 trials (RECONNECT)](https://pubmed.ncbi.nlm.nih.gov/31599840/) (rct, n=1267, 2019): 1.75 mg as needed over 24 weeks modestly raised desire (FSFI-desire +0.35 vs placebo) and lowered distress in premenopausal women; nausea, flushing and headache in 10% or more.
- [Simon et al. 2019: long-term safety and efficacy of bremelanotide (RECONNECT open-label extension)](https://pubmed.ncbi.nlm.nih.gov/31599847/) (open-label, n=684, 2019): Over 52 weeks no new safety signals; nausea 40%, flushing 21%, headache 12%, and only 272 of 684 completed the extension.
- [Clayton et al. 2016: bremelanotide for female sexual dysfunctions in premenopausal women, phase 2b dose-finding trial](https://pubmed.ncbi.nlm.nih.gov/27181790/) (rct, n=327, 2016): 1.25-1.75 mg raised satisfying sexual events by 0.7 vs 0.2 a month on placebo and improved FSFI and distress scores.
- [Safarinejad & Hosseini 2008: salvage of sildenafil failures with bremelanotide](https://pubmed.ncbi.nlm.nih.gov/18206919/) (rct, n=342, 2008): Intranasal 10 mg helped 33.5% of men who had not responded to sildenafil vs 8.5% on placebo, with more adverse effects; the journal issued an expression of concern about this paper in 2023.

## Sources

- [Vyleesi full prescribing information](https://www.vyleesi.com/docs/Vyleesi-Full-Prescribing-Information.pdf)